Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy
Identifieur interne : 000572 ( Main/Exploration ); précédent : 000571; suivant : 000573Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy
Auteurs : C. A. Guevara [Royaume-Uni] ; C. R. Blain [Royaume-Uni] ; D. Stahl [Royaume-Uni] ; D. J. Lythgoe [Royaume-Uni] ; P. N. Leigh [Royaume-Uni] ; G. J. Barker [Royaume-Uni]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2010-09.
English descriptors
- KwdEn :
Abstract
Background and purpose: Magnetic resonance spectroscopy (MRS) allows the measurement of a number of brain tissue metabolites in vivo, including N‐acetylaspartate (NAA), a putative marker of neuronal integrity. Unlike single voxel MRS, magnetic resonance spectroscopic imaging (MRSI) enables quantification of these metabolites simultaneously from multiple anatomically localized voxels. Both single voxel MRS and MRSI allow the absolute quantification of these metabolites and, when combined with tissue segmentation, can give accurate metabolite concentrations even in the presence of partial volume effects from nearby cerebrospinal fluid. Methods: Using MRSI with cubic voxels with a nominal volume of 1.0 cm3, we tested the hypothesis that concentrations of NAA in the basal ganglia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) would show differences compared to Parkinson’s disease (IPD). NAA values (in mM) from MRSI voxels centred to the putamen, pallidum and thalamus were obtained from 11 patients with IPD, 11 with MSA‐P, six with MSA‐C, 13 with PSP and 18 controls. The mean concentrations of NAA and its bulk grey and white matter values were also estimated over the whole brain slab. Results: N‐acetylaspartate concentrations in the pallidum, putamen and lentiform nucleus were significantly lower in patients with MSA‐P and PSP compared to IPD and controls. The putaminal values were also significantly reduced in PSP compared to MSA‐P. There were no significant differences between groups in the thalamus and over the whole brain slab. Conclusion: Our findings support the notion that MRSI can potentially quantify basal ganglia cellular pathology in MSA and PSP.
Url:
DOI: 10.1111/j.1468-1331.2010.03010.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy</title><author><name sortKey="Guevara, C A" sort="Guevara, C A" uniqKey="Guevara C" first="C. A." last="Guevara">C. A. Guevara</name></author><author><name sortKey="Blain, C R" sort="Blain, C R" uniqKey="Blain C" first="C. R." last="Blain">C. R. Blain</name></author><author><name sortKey="Stahl, D" sort="Stahl, D" uniqKey="Stahl D" first="D." last="Stahl">D. Stahl</name></author><author><name sortKey="Lythgoe, D J" sort="Lythgoe, D J" uniqKey="Lythgoe D" first="D. J." last="Lythgoe">D. J. Lythgoe</name></author><author><name sortKey="Leigh, P N" sort="Leigh, P N" uniqKey="Leigh P" first="P. N." last="Leigh">P. N. Leigh</name></author><author><name sortKey="Barker, G J" sort="Barker, G J" uniqKey="Barker G" first="G. J." last="Barker">G. J. Barker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6AB28CC0CC4AADC40AF8E7E78A31772B8CBB657E</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1468-1331.2010.03010.x</idno><idno type="url">https://api.istex.fr/document/6AB28CC0CC4AADC40AF8E7E78A31772B8CBB657E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000670</idno><idno type="wicri:Area/Main/Curation">000586</idno><idno type="wicri:Area/Main/Exploration">000572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy</title><author><name sortKey="Guevara, C A" sort="Guevara, C A" uniqKey="Guevara C" first="C. A." last="Guevara">C. A. Guevara</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry</wicri:orgArea></affiliation></author><author><name sortKey="Blain, C R" sort="Blain, C R" uniqKey="Blain C" first="C. R." last="Blain">C. R. Blain</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry</wicri:orgArea></affiliation></author><author><name sortKey="Stahl, D" sort="Stahl, D" uniqKey="Stahl D" first="D." last="Stahl">D. Stahl</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biostatistics and Computing, King’s College London, Institute of Psychiatry, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lythgoe, D J" sort="Lythgoe, D J" uniqKey="Lythgoe D" first="D. J." last="Lythgoe">D. J. Lythgoe</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry</wicri:orgArea></affiliation></author><author><name sortKey="Leigh, P N" sort="Leigh, P N" uniqKey="Leigh P" first="P. N." last="Leigh">P. N. Leigh</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry</wicri:orgArea></affiliation></author><author><name sortKey="Barker, G J" sort="Barker, G J" uniqKey="Barker G" first="G. J." last="Barker">G. J. Barker</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-09">2010-09</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1193">1193</biblScope><biblScope unit="page" to="1202">1202</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">6AB28CC0CC4AADC40AF8E7E78A31772B8CBB657E</idno><idno type="DOI">10.1111/j.1468-1331.2010.03010.x</idno><idno type="ArticleID">ENE3010</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>magnetic resonance spectroscopic imaging</term><term>multiple system atrophy</term><term>progressive supranuclear palsy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and purpose: Magnetic resonance spectroscopy (MRS) allows the measurement of a number of brain tissue metabolites in vivo, including N‐acetylaspartate (NAA), a putative marker of neuronal integrity. Unlike single voxel MRS, magnetic resonance spectroscopic imaging (MRSI) enables quantification of these metabolites simultaneously from multiple anatomically localized voxels. Both single voxel MRS and MRSI allow the absolute quantification of these metabolites and, when combined with tissue segmentation, can give accurate metabolite concentrations even in the presence of partial volume effects from nearby cerebrospinal fluid. Methods: Using MRSI with cubic voxels with a nominal volume of 1.0 cm3, we tested the hypothesis that concentrations of NAA in the basal ganglia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) would show differences compared to Parkinson’s disease (IPD). NAA values (in mM) from MRSI voxels centred to the putamen, pallidum and thalamus were obtained from 11 patients with IPD, 11 with MSA‐P, six with MSA‐C, 13 with PSP and 18 controls. The mean concentrations of NAA and its bulk grey and white matter values were also estimated over the whole brain slab. Results: N‐acetylaspartate concentrations in the pallidum, putamen and lentiform nucleus were significantly lower in patients with MSA‐P and PSP compared to IPD and controls. The putaminal values were also significantly reduced in PSP compared to MSA‐P. There were no significant differences between groups in the thalamus and over the whole brain slab. Conclusion: Our findings support the notion that MRSI can potentially quantify basal ganglia cellular pathology in MSA and PSP.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Guevara, C A" sort="Guevara, C A" uniqKey="Guevara C" first="C. A." last="Guevara">C. A. Guevara</name></region><name sortKey="Barker, G J" sort="Barker, G J" uniqKey="Barker G" first="G. J." last="Barker">G. J. Barker</name><name sortKey="Blain, C R" sort="Blain, C R" uniqKey="Blain C" first="C. R." last="Blain">C. R. Blain</name><name sortKey="Leigh, P N" sort="Leigh, P N" uniqKey="Leigh P" first="P. N." last="Leigh">P. N. Leigh</name><name sortKey="Lythgoe, D J" sort="Lythgoe, D J" uniqKey="Lythgoe D" first="D. J." last="Lythgoe">D. J. Lythgoe</name><name sortKey="Stahl, D" sort="Stahl, D" uniqKey="Stahl D" first="D." last="Stahl">D. Stahl</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6AB28CC0CC4AADC40AF8E7E78A31772B8CBB657E
|texte= Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |